214 related articles for article (PubMed ID: 33884171)
1. A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria.
Barber J; Sikakana P; Sadler C; Baud D; Valentin JP; Roberts R
Toxicol Res (Camb); 2021 Mar; 10(2):203-213. PubMed ID: 33884171
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts.
Meyers MJ; Goldberg DE
Curr Top Med Chem; 2012; 12(5):445-55. PubMed ID: 22242846
[TBL] [Abstract][Full Text] [Related]
3. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.
Moura PA; Dame JB; Fidock DA
Antimicrob Agents Chemother; 2009 Dec; 53(12):4968-78. PubMed ID: 19752273
[TBL] [Abstract][Full Text] [Related]
4. A dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapy.
Munsamy G; Agoni C; Soliman MES
J Cell Biochem; 2019 May; 120(5):7876-7887. PubMed ID: 30430636
[TBL] [Abstract][Full Text] [Related]
5. Unveiling a New Era in Malaria Therapeutics: A Tailored Molecular Approach Towards the Design of Plasmepsin IX Inhibitors.
Munsamy G; Soliman MES
Protein J; 2019 Dec; 38(6):616-627. PubMed ID: 31586296
[TBL] [Abstract][Full Text] [Related]
6. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Hodder AN; Christensen J; Scally S; Triglia T; Ngo A; Birkinshaw RW; Bailey B; Favuzza P; Dietrich MH; Tham WH; Czabotar PE; Lowes K; Guo Z; Murgolo N; Lera Ruiz M; McCauley JA; Sleebs BE; Olsen D; Cowman AF
Structure; 2022 Jul; 30(7):947-961.e6. PubMed ID: 35460613
[TBL] [Abstract][Full Text] [Related]
7. Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).
Cheuka PM; Dziwornu G; Okombo J; Chibale K
J Med Chem; 2020 May; 63(9):4445-4467. PubMed ID: 31913032
[TBL] [Abstract][Full Text] [Related]
8. Malaria parasite plasmepsins: More than just plain old degradative pepsins.
Nasamu AS; Polino AJ; Istvan ES; Goldberg DE
J Biol Chem; 2020 Jun; 295(25):8425-8441. PubMed ID: 32366462
[TBL] [Abstract][Full Text] [Related]
9. Plasmepsins as antimalarial targets.
Berry C
Curr Opin Drug Discov Devel; 2000 Sep; 3(5):624-9. PubMed ID: 19649890
[TBL] [Abstract][Full Text] [Related]
10. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
Bobrovs R; Jaudzems K; Jirgensons A
J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
[TBL] [Abstract][Full Text] [Related]
11. Antimalarials: Review of Plasmepsins as Drug Targets and HIV Protease Inhibitors Interactions.
Miller Iii WA; Teye J; Achieng AO; Mogire RM; Akala H; Ong'echa JM; Rathi B; Durvasula R; Kempaiah P; Kwofie SK
Curr Top Med Chem; 2019; 18(23):2022-2028. PubMed ID: 30499404
[TBL] [Abstract][Full Text] [Related]
12. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
13. Antimalarial Phytochemicals Identification from
Shah AP; Parmar GR; Sailor GU; Seth AK
Folia Med (Plovdiv); 2019 Dec; 61(4):584-593. PubMed ID: 32337872
[TBL] [Abstract][Full Text] [Related]
14. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
[TBL] [Abstract][Full Text] [Related]
15. Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X.
Li F; Bounkeua V; Pettersen K; Vinetz JM
Malar J; 2016 Feb; 15():111. PubMed ID: 26911483
[TBL] [Abstract][Full Text] [Related]
16. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
Favuzza P; de Lera Ruiz M; Thompson JK; Triglia T; Ngo A; Steel RWJ; Vavrek M; Christensen J; Healer J; Boyce C; Guo Z; Hu M; Khan T; Murgolo N; Zhao L; Penington JS; Reaksudsan K; Jarman K; Dietrich MH; Richardson L; Guo KY; Lopaticki S; Tham WH; Rottmann M; Papenfuss T; Robbins JA; Boddey JA; Sleebs BE; Sabroux HJ; McCauley JA; Olsen DB; Cowman AF
Cell Host Microbe; 2020 Apr; 27(4):642-658.e12. PubMed ID: 32109369
[TBL] [Abstract][Full Text] [Related]
17. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
[TBL] [Abstract][Full Text] [Related]
18. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.
Andrews KT; Fairlie DP; Madala PK; Ray J; Wyatt DM; Hilton PM; Melville LA; Beattie L; Gardiner DL; Reid RC; Stoermer MJ; Skinner-Adams T; Berry C; McCarthy JS
Antimicrob Agents Chemother; 2006 Feb; 50(2):639-48. PubMed ID: 16436721
[TBL] [Abstract][Full Text] [Related]
19. New directions for protease inhibitors directed drug discovery.
Hamada Y; Kiso Y
Biopolymers; 2016 Nov; 106(4):563-79. PubMed ID: 26584340
[TBL] [Abstract][Full Text] [Related]
20. Aspartic proteases from Plasmodium chabaudi: a rodent model for human malaria.
Martins TM; Novo C; do Rosário VE; Domingos A
Acta Trop; 2003 Dec; 89(1):1-12. PubMed ID: 14636976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
